Abstract
Aim:The implications of molecular biomarkers IDH1/2 mutations and MGMT gene promoter methylation were evaluated for prognostic outcome of glioma patients.Materials & methods:Glioma cases were analyzed for IDH1/2 mutations and MGMT promoter methylation by DNA sequencing and methylation-specific PCR, respectively.Results:Mutations found in IDH1/2 genes totaled 63.4% (N = 40) wherein IDH1 mutations were significantly associated with oligidendrioglioma (p = 0.005) and astrocytoma (p = 0.0002). IDH1 mutants presented more, 60.5% in MGMT promoter-methylated cases (p = 0.03). IDH1 mutant cases had better survival for glioblastoma and oligodendrioglioma (log-rank p = 0.01). Multivariate analysis confirmed better survival in MGMT methylation carriers (hazard ratio [HR]: 0.59; p = 0.031). Combination of both biomarkers showed better prognosis on temozolomide (p < 0.05).Conclusion:IDH1/2 mutations proved independent prognostic factors in glioma and associated with MGMT methylation for better survival.
Highlights
Glioma cases were analyzed for IDH1/2 mutations by DNA sequencing and MGMT methylation through methylation-specific PCR
Mutations found in IDH1/2 genes totaled 63.4% in glioma cases (N = 40)
A significant association was observed between IDH1 mutations and oligidendrioglioma (p = 0.005) and astrocytoma (p = 0.0002)
Summary
The implications of molecular biomarkers IDH1/2 mutations and MGMT gene promoter methylation were evaluated for prognostic outcome of glioma patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
